Research Study

A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine
Principal Investigator 
Ric Procyshyn

Overview

Body Locations and Systems 
Brain
Disorders and Conditions 
Schizophrenia
ClinicalTrials.gov# 
NCT02286206
Status 
Recruiting
Study Start/End 
Jan 15, 2015 to Jul 5, 2017
Locations 
UBC Hospital
Name/Title 
Heidi Boyda, Post Doctoral Fellow
Phone 
604-822-7500
Email Address 
hnboyda@gmail.com
Purpose of Study 

The objectives of this 15-day study are:

  • To compare steady-state trough plasma concentrations of clozapine and its metabolite norclozapine when given once daily and twice daily (at the same total daily dose)
  • To determine if frequency of clozapine administration has an effect on:
    • Symptoms of schizophrenia
    • Adverse effects of clozapine
    • Fasting blood glucose, lipids, creatinine, and urea
    • Weight and waist circumference
Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.